In thin basement membrane nephropathy with proteinuria, renin-angiotensin-aldosterone system inhibitors (such as captopril and valsartan) and aldosterone inhibitors (spironolactone) can be used to reduce proteinuria.
Thin basement membrane nephropathy (TBMN) is mainly characterized by persistent polymorphic microscopic hematuria and occasionally by polymorphic hematuria after upper respiratory tract infection or strenuous exercise, and the pathology is characterized by diffuse thinning of the glomerular basement membrane (GBM) under electron microscopy.
TBMN is mostly benign, but some patients with TBMN may develop proteinuria, hypertension or even chronic renal insufficiency, which requires long-term follow-up, monitoring of blood pressure, and regular urine routine and renal function tests. Avoid infection, exertion and application of nephrotoxic drugs.
For patients who only show hematuria with normal blood pressure and normal renal function, there is no need for special medication, regular review is sufficient. Patients with proteinuria can be given drugs such as renin-angiotensin-aldosterone system inhibitors (e.g., captopril, valacyclovir) and aldosterone inhibitors (spironolactone) to reduce proteinuria and delay the progression of renal disease.
When proteinuria occurs in thin basement membrane nephropathy, it is recommended to go to the hospital as soon as possible, and use medication under the guidance of physicians.